Q2 2026 delivered three simultaneous pivots in longevity and human performance: Foundayo (orforglipron) became the first oral GLP-1 pill for weight loss (FDA-approved April 1), Isomorphic Labs closed a $2.1B Series B · the largest private AI drug discovery round in history · and NewLimit raised $435M from Founders Fund and Lilly Ventures to bring epigenetic reprogramming into human clinical trials. This report maps each layer of the convergence with primary-source data and three decisions that cannot wait for Q3.